Research at the Clayton Foundation has led to several FDA approved drugs, medical devices and diagnostic assays along with the following pipeline in development by our licensees.
Pipeline
- Overview
- Research Institutions
- Research Projects
- Products Brought to Market
- Pipeline
- Portfolio Companies
- Licensees
- Contact Us
Clinical Pipeline
LentiGlobin
Indication: Sickle Cell Disease
Phase II / III
Oral Vimo-001
Indication: Solid Tumors
Phase I
Pre-Clinical Pipeline
Dengue Virus Vaccine
Indication: 4 serotype dengue vaccine
IND in preparation
Chikungunya Virus Vaccine
Indication: vaccine to chikungunya
IND enabling studies
Zika Virus Vaccine
Indication: vaccine to zika
IND enabling studies
RT-200
Indication: Type II Diabetes
Advanced Preclinical
RT-300
Indication: Congestive Heart Failure
Preclinical
RT-400
Indication: Acute decompensated heart failure
Preclinical
GrB-Fc-SD1
Indication: Mesotheliomas & Pancreatic Cancers
Preclinical
GrB-Fc-IT4
Indication: Breast and other solid tumors
Preclinical
GrB-Fc-VEGF
Indication: Wet AMD & Choroidal Neovascularization
Preclinical
Early Stage Pipeline
JamC mAb
Indication: B Cell Lymphomas
Animal in vivo POC
Olfml3 mAb
Indication: Metastatic breast cancer
Animal in vivo POC
HI P. Goldsteinii
Indication: Osteoporosis and Obesity
Preclinical
HDAC inhibitors for TB
Valproic acid to treat TB
Drug repurposing
